How is semaglutide dosed, and how many units is a dose?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Semaglutide and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
For weight reduction in adults, the Wegovy label starts at 0.25 mg once weekly, gives 1.7 mg or 2.4 mg (recommended) as maintenance and allows up to 7.2 mg once weekly after 4 weeks on 2.4 mg where additional weight reduction is clinically indicated; the Ozempic label, for adults with type 2 diabetes, tops out at 2 mg once weekly.12
The guide's example
250 mcg of Semaglutide from a 10 mg vial mixed with 2 mL is 5 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units, 1,000 mcg is 20 units, 2,400 mcg is 48 units | 2.5 mg/mL: 250 mcg is 10 units, 500 mcg is 20 units, 1,000 mcg is 40 units, 2,400 mcg is 96 units |
| 10 mg | 10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units, 1,000 mcg is 10 units, 2,400 mcg is 24 units | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units, 1,000 mcg is 20 units, 2,400 mcg is 48 units |
How semaglutide is supplied, and how many units a dose is
| Product | Strength | Volume per dose |
|---|---|---|
| Ozempic 0.25 mg pen (European product information) | 1.34 mg/mL | 0.19 mL3 |
The FDA says instructions with compounded semaglutide may give the dose in units, whose volume varies with concentration, and that a single compounder may offer several concentrations, so the same units can be a different dose.4
A worked example with an illustrative vial that no label or regulator lists: a 10 mg vial mixed with 2 mL is 5 mg/mL, so 250 mcg is 0.05 mL, or 5 units on a U-100 insulin syringe, whose scale is made for insulin at 100 units per mL; the FDA describes the same 5-unit dose on that syringe.54
250 mcg of Semaglutide from a 10 mg vial mixed with 2 mL is 5 units on a U-100 syringe.
The calculator is at the top of the page
No label gives a powder or a mix for semaglutide: DailyMed lists injection solutions and tablets only, and the European Ozempic information describes a pre-filled pen solution, so no label says which water or how much.63
The FDA says several reports describe providers miscalculating doses converting milligrams to units or milliliters, giving five to 10 times the intended dose.4
What the labels give
The Wegovy label steps the once-weekly injection through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, four weeks each, over weeks 1 through 16, in adults and pediatric patients aged 12 years and older.1 Maintenance is 1.7 mg or 2.4 mg once weekly, and 7.2 mg once weekly is allowed for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated.1 The Wegovy label also lists tablets of 1.5 mg, 4 mg, 9 mg and 25 mg, with 25 mg once daily as maintenance.1
For type 2 diabetes, the Ozempic label starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly.2 If additional glycemic control is needed, the label raises the dose to 1 mg once weekly after at least 4 weeks on 0.5 mg, and to 2 mg, its maximum, after at least 4 weeks on 1 mg.2
What STEP 1 and STEP 5 gave
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| STEP 1 (Wilding 2021) | 0.25 mg stepping to 2.4 mg once weekly, against placebo, both with lifestyle intervention | 1961 adults with a BMI of 30 or greater (27 or greater with a weight-related condition), without diabetes | 68 weeks78 |
| STEP 5 (Garvey 2022) | 2.4 mg once weekly, against placebo, both with behavioral intervention | 304 adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes (152 per arm) | To week 1049 |
| Phase 2 dose-ranging trial (O'Neil 2018) | 0.05, 0.1, 0.2, 0.3 or 0.4 mg once daily, against liraglutide 3.0 mg and placebo, all with diet and physical activity counselling | 957 adults with a BMI of 30 kg/m2 or more, without diabetes | 52 weeks1011 |
In STEP 1 (Wilding 2021; 1961 adults), mean body weight change to week 68 was -14.9% with semaglutide 2.4 mg once weekly against -2.4% with placebo.87 In STEP 5 (Garvey 2022; 304 adults), mean body weight change to week 104 was -15.2% with semaglutide 2.4 mg once weekly against -2.6% with placebo.9
How long a pen or vial keeps
After first use, the Wegovy label gives the FlexTouch pen 56 days at 15 to 30 degrees C or in a refrigerator, while its instructions for use give 20 to 25 degrees C or a refrigerator; the European information gives an in-use Ozempic pen 6 weeks (4-dose) or 8 weeks (8-dose) below 30 degrees C or in a refrigerator.13 The US Ozempic label gives a pen in use 56 days at 15 to 30 degrees C or in a refrigerator.2 The FDA says a multiple-dose compounded vial is discarded within 28 days after first use, even if medication remains or the compounder's instructions say longer.12
Frequently asked questions
What strengths do pens and syringes come in?
The US Ozempic label lists pens of 2 mg/3 mL (0.68 mg/mL) for doses of 0.25 mg and 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 1 mg and 8 mg/3 mL (2.68 mg/mL) for 2 mg, and single-dose prefilled syringes of 0.25 mg, 0.5 mg or 1 mg per 0.5 mL.2
What is semaglutide microdosing?
A 2026 review in Minerva Endocrinology says the evidence on microdosing is mostly anecdotal and that its use is not supported by manufacturers, scientific societies or drug regulatory agencies.13 One literature search for "semaglutide microdosing" returned only commentary, reviews and record analyses, and no human trial.
How does compounded semaglutide differ from Ozempic or Wegovy?
The FDA says compounded drugs are not FDA approved, so it does not review them for safety, effectiveness or quality before marketing.12 Australia's TGA says a compounded medicine can have a different strength and ingredients from approved medicines, and that compounded semaglutide-like products are not identical to Ozempic.14
References
- Novo Nordisk (via DailyMed). WEGOVY (semaglutide) injection and tablets. Prescribing information. 2026. dailymed.nlm.nih.gov
- Novo Nordisk (via DailyMed). OZEMPIC (semaglutide) injection. Prescribing information. 2026. dailymed.nlm.nih.gov
- European Medicines Agency / Novo Nordisk. Ozempic: summary of product characteristics (EPAR product information). 2026. ema.europa.eu
- US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. 2024. fda.gov
- Eli Lilly (via DailyMed). HUMULIN R (insulin human) injection. Prescribing information. 2026. dailymed.nlm.nih.gov
- US National Library of Medicine, DailyMed. DailyMed listing of semaglutide drug labels. 2026. dailymed.nlm.nih.gov
- ClinicalTrials.gov, Novo Nordisk A/S. STEP 1 registry record (NCT03548935). 2021. clinicaltrials.gov
- New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov
- Nature Medicine. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. 2022. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov, Novo Nordisk A/S. Once-daily semaglutide phase 2 registry record (NCT02453711). 2018. clinicaltrials.gov
- The Lancet. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a dose-ranging phase 2 trial. 2018. pubmed.ncbi.nlm.nih.gov
- US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. fda.gov
- Minerva Endocrinology. Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks. 2026. pubmed.ncbi.nlm.nih.gov
- Therapeutic Goods Administration (Australia). Compounding safety information: semaglutide-like products. 2023. tga.gov.au